图片来源:摄图网
近日,港股上市公司德琪医药发布公告称,与翰森制药达成独家合作协议,由翰森制药负责塞利尼索在中国大陆的商业化, 德琪医药将获最高2亿元首付款及最高5.35亿元里程碑付款。
据了解,塞利尼索是德琪医药首个上市商业化产品,从Karyopharm引进,...查看全文
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-048396 Size: 7 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-048397 Size: 7 KB 网页链接
$Karyopharm(KPTI)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001209191-22-046824 Size: 11 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-045718 Size: 6 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-044561 Size: 4 KB 网页链接
$Karyopharm(KPTI)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-22-014788 Act: 34 Size: 10 MB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-22-211832 Act: 34 Size: 278 KB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, item 5.02 Accession Number: 0001193125-22-204195 Act: 34 Size: 145 KB 网页链接
$Karyopharm(KPTI)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-22-041774 Size: 4 KB 网页链接
$Karyopharm(KPTI)$ 8-K Current report, item 1.02 Accession Number: 0001193125-22-174750 Act: 34 Size: 146 KB 网页链接